Technology | May 19, 2015

FDA Clears Sutureless Epicardial Pacing Leads

Leads can be used in patients contraindicated for traditional leads

Greatbatch Medical, Myopore Sutureless Myocardial Pacing Lead

May 19, 2015 — A new epicardial pacing lead has been cleared by the U.S. Food and Drug Administration (FDA) as an option for the implant of a pacemaker, defibrillator, or cardiac resynchronization therapy (CRT) device. The lead is indicated when other types of leads cannot be implanted. Examples include patients who have small veins, congenital heart disease, abnormalities of the tricuspid valve or when other leads are already in place, preventing additional leads in the veins.

The Myopore Sutureless Myocardial Pacing Lead from Greatbatch Medical is a surgically implanted, insulated and sutureless wire with a screw-in tip that is part of a permanently implanted pacemaker, defibrillator or CRT device. The lead is implanted by opening the chest or a making a small incision under the breastbone. It is then placed on the surface of the heart muscle so the screw-in tip end can electrically stimulate (pace) the ventricles.

When placed on the surface of the heart as part of a pacemaker, the Myopore Lead paces the heart to assure that it beats at an appropriate rate. A CRT device uses two leads, one to pace each ventricle, either of which may be a Myopore Lead. A CRT device with two leads is intended to coordinate and improve the ventricles' timing to reduce symptoms of heart failure.

The Myopore Lead should not be used when a patient's heart is too thin or damaged and should not be implanted on the surface of the atria.

For more information: www.greatbatchmedical.com

Related Content

His Corrective Pacing Effective as an Initial Strategy for Heart Failure Cardiac Resynchronization CRT therapy vs. biventricular pacing (BiV) as a first-line strategy. #HRS #HRS19 #HRS2019
News | Cardiac Resynchronization Therapy Devices (CRT) | May 15, 2019 | Dave Fornell, Editor
May 15, 2019 — A pilot trial has shown His pacing in...
Biotronik Launches Acticor DX and CRT-DX Devices in U.S.
News | Cardiac Resynchronization Therapy Devices (CRT) | April 29, 2019
Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and CRT-DX devices....
Biotronik Launches Acticor and Rivacor ICD and CRT-D Devices in Europe
News | Cardiac Resynchronization Therapy Devices (CRT) | April 18, 2019
Biotronik announced the European market release of what it calls the world’s smallest implantable cardioverter...
Medtronic AdaptivCRT Feature Associated with Improved Heart Failure Patient Survival
News | Cardiac Resynchronization Therapy Devices (CRT) | May 22, 2018
Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved patient survival....
Medtronic Recalls CRT-Ds and ICDs Due to Manufacturing Error Preventing Electrical Shock Delivery
News | Cardiac Resynchronization Therapy Devices (CRT) | February 26, 2018
The U.S. Food and Drug Administration (FDA) announced that Medtronic is recalling certain implantable cardioverter...
Abbott Announces MR-Conditional Labeling for Quadra Assura CRT-D and Fortify Assura ICD
Technology | Cardiac Resynchronization Therapy Devices (CRT) | January 03, 2018
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT) | August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT) | July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Overlay Init